After adjusting for sex, tumor grade, age group, and IDH1 mutation status, the median survival of all patients with PTPμ low was about half as long, 18.6 months, as those with PTPμ high staining, where the median survival was 38.2 months (Figure 2b). Here, IDH1 is linked to neoplasm.